Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: GOG 9920 Principal Investigator: Mutch, David
Title: A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Description: The purpose of this study is to test the safety of a chemotherapy treatment that includes both intravenous (IV – given by vein) and intraperitoneal (IP- given directly into the abdomen) administration of drugs for patients with high-risk endometrial cancer. Currently, intraperitoneal chemotherapy i...MORE
___________________________________________________________________________________________________
 Number: GOG 258 Principal Investigator: Mutch, David
Title: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Description: Patients with endometrial cancer have been treated with radiation and chemotherapy. Today most women with endometrial cancer whose cancer has spread outside the uterus generally receive chemotherapy. Women who have disease outside the uterus may also receive radiation to the areas where the diseas...MORE
___________________________________________________________________________________________________
 Number: 201105400 Principal Investigator: Mutch, David
Title: Formation of a Tissue Bank for Gynecologic Malignancies
Description: The purpose of this study is to collect specimens (i.e., tissue obtained during surgery and/or blood) and related information from women who are undergoing surgery for a gynecologic condition. Specimens and related information that are collected for this research study will be used for future cance...MORE
___________________________________________________________________________________________________
 Number: 201103375 Principal Investigator: Mutch, David
Title: Defective DNA Mismatch Repair in Endometrial Cancers
___________________________________________________________________________________________________
 Number: 201105123 Principal Investigator: Mutch, David
Title: SPORE In Endometrial Cancer
___________________________________________________________________________________________________
 Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE
___________________________________________________________________________________________________
 Number: P2C MC0845 Principal Investigator: Picus, Joel
Title: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid, or Islet Cell Cancer
Description: This study is being done to learn what effects (good and bad) the combination of temsirolimus and bevacizumab has on you and your cancer. The combination of these two drugs is currently being tested in patients with kidney cancer through another study. Although preliminary results from this study ar...MORE
___________________________________________________________________________________________________
 Number: 201107068 Principal Investigator: Lockhart, A. Craig
Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment
Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE
___________________________________________________________________________________________________